Table 2:

Modified Behavioural Pain Scale scores during 2-, 4-, 6- and 12-month vaccinations

VaccinationScore, mean ± SD
Placebo controlVideoVideo–sucroseVideo–sucrose–lidocaine
Baseline*, mo
23.0 ± 1.33.1 ± 1.42.9 ± 1.32.8 ± 1.2
42.6 ± 1.12.4 ± 0.82.4 ± 0.92.3 ± 0.8
62.4 ± 0.82.2 ± 0.52.3 ± 0.72.4 ± 0.7
122.7 ± 1.3§2.8 ± 1.32.7 ± 1.32.7 ± 1.3
Needle, mo
28.2 ± 0.98.2 ± 0.88.1 ± 0.87.9 ± 1.1
47.2 ± 1.26.8 ± 1.36.7 ± 1.46.3 ± 1.4
65.1 ± 2.14.7 ± 2.25.1 ± 2.24.4 ± 2.0
126.4 ± 1.76.9 ± 1.56.9 ± 1.56.4 ± 1.9
Recovery, mo
24.6 ± 1.64.8 ± 1.84.9 ± 1.94.8 ± 1.8
44.3 ± 1.74.0 ± 1.44.2 ± 1.94.3 ± 1.8
62.6 ± 1.02.5 ± 0.92.5 ± 1.12.4 ± 0.9
123.6 ± 1.84.0 ± 1.84.1 ± 1.74.0 ± 1.8
  • Note: Baseline = 15 seconds preceding vaccine injection, Needle = first 15 seconds after vaccine injection, Recovery = first 15 seconds starting 1 minute after vaccine injection, SD = standard deviation.

  • * Analysis of variance showed a time effect (p < 0.001), but no evidence of a difference among groups (p = 0.4) at baseline.

  • Analysis of variance showed time (p < 0.001) and group effects (p = 0.003) during the needle; scores were lower for the video–sucrose–lidocaine group v. placebo (p < 0.001), video (p = 0.003), and video–sucrose (p = 0.005) groups, respectively. There were no other between-group differences.

  • Analysis of variance showed a time effect (p < 0.001), but no evidence of a difference among groups (p = 0.98) at recovery.

  • § n = 74.